News Archive

Newly published research led by the Pediatrix Medical Group and the Duke Clinical Research Institute’s Rachel Greenberg, MD, MB, MHS, assessed the impact of COVID-19 on pregnant women and infants admitted to the neonatal intensive care unit (NICU). It is believed to be the largest study evaluating the prevalence of COVID-19 within a neonatal population and associated hospital outcomes.

Results from a Duke Clinical Research Institute study that were recently published in JAMA Network Open expand the depth of understanding of how dexamethasone can improve outcomes among patients ho

Patients who have diabetes and heart disease do best when both conditions are treated according to established guidelines, but far too many are not prescribed the effective therapies. A recent study — designed and led by the Duke Clinical Research Institute (DCRI) and an academic steering committee — found that a coordinated care approach between cardiologists and diabetes specialists resulted in more patients receiving the recommended therapies. The study was funded by Boehringer Ingelheim and Eli Lilly and Company.

A recent trial of empagliflozin expanded the understanding of how the drug can slow chronic kidney disease in a wide range of patients, lowering the risk of disease progression and death from cardi

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between parti

A study by the Duke Clinical Research Institute comparing three treatment methods of preventing malaria in children with sickle cell anemia (SCA) found one method reduces common complications of the disease. EPiTOMISE: Enhancing Preventive Therapy Of Malaria in Children with Sickle cell anemia in East Africa, was conducted among children with SCA in Homa Bay, Kenya, where malaria is common. It evaluated the effects of a monthly combination of sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) or a monthly combination of dihydroartemisinin-piperaquine (DP) against the standard of care in Kenya, Proguanil.

A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with new-onset chest pain.

Less complex heart patients may benefit, but not without risk

In a head-to-head comparison of two so-called ‘water pills’ that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths,

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the